Human T-lymphotropic virus type III (HTLV-I)/lymphadenopathy-associated virus (LAV) is a newly discovered lymphotropic retrovirus that is cytopathic for helper/inducer T cells in vitro. This virus is the etiologic agent of the acquired immunodeficiency syndrome and related diseases. In the current study, we tested the capacity of purine and pyrimidine nucleoside derivatives to inhibit the infectivity and cytopathic effect of human T-lymphotropic virus type Ill in vitro. With the ribose moiety of the molecule in a 2',3'-dideoxy configuration, every purine (adenosine, guanosine, and inosine) and pyrimidine (cytidine and thymidine) nucleoside tested suppressed the virus, although the thymidine derivative seemed to have substantially less activity in our system than the others. In general, we observed essentially complete suppression of the virus at doses that were lower by a factor of 10 to 20 than those needed to inhibit the proliferation of the target T cells and the immune reactivity of normal T cells in vitro. An analysis of five adenosine congeners, which differed only in the sugar moiety, revealed that reduction (an absence of hydroxyl determinants) at both the 2' and 3' carbons of the ribose was necessary for an anti-viral effect, and an additional reduction at the 5' carbon nullified the anti-viral activity. These observations may be of value in developing a new class of experimental drugs for the therapy of human T-lymphotropic virus type III infections.
Human T-lymphotropic virus type III (HTLV-III)/ lymphadenopathy-associated virus (LAV) is a lymphotropic retrovirus which is cytopathic for helper/inducer T cells in vitro (1) (2) (3) (4) (5) (6) (7) . This virus is the etiologic agent of the acquired immunodeficiency syndrome (AIDS) and related diseases (8, 9) . To date, over 14,000 cases of AIDS have been reported in the United States; the incidence and prevalence of this disease continue to increase. AIDS is almost always fatal within 1 to 2 years after the first clinical manifestations of illness. This disease was initially described and characterized in four high-risk groups (homosexual men, hemophiliacs, Haitians, and intravenous drug abusers); however, individuals belonging to no apparent high-risk groups have developed the disease. AIDS is generally spread by intimate sexual contact or by the administration of blood products, and occasionally by the maternal-fetal route. Many patients who develop AIDS are asymptomatic when they transmit their disease to contacts because a 6-month to 5-year (or more) latency interval may exist between infection and clinical manifestations of illness (10) .
Although a number of anti-viral agents are now being considered for the experimental therapy of AIDS (11) (12) (13) (14) (15) (16) (17) , to date no therapy has been shown to cure HTLV-III/LAV infection or restore the underlying immunodeficiency. Moreover, the chronicity of infection (8, 10) and the propensity of the virus to infect the brain (18, 19) make it necessary to explore new classes of drugs that have the potential for oral administration and penetration across the blood-brain barrier. In the current study, we report that with the ribose moiety of the molecule in a 2' ,3'-dideoxy configuration, every purine (adenosine, guanosine, and inosine) and pyrimidine (cytidine and thymidine) nucleoside tested suppressed the infectivity and the cytopathic effect of HTLV-III/LAV in vitro at concentrations that do not affect the growth and immune functions of T cells.
MATERIALS AND METHODS
HTLV-IH/LAV Virus. HTLV-IIIB was obtained from the culture supernatant of HTLV-IIIB-producing H9 (H9/ HTLV-IIIB) cells as described (1) . The virus was prepared to contain approximately 6 x 1010 virus particles per ml. The number of virus particles were determined by electron microscopy. In some experiments, irradiated (10,000 rad; 1 rad = 0.01 Gy) H9/HTLV-IIIB cells were used as a source of infectious virions.
Nucleosides. 2',3'-Dideoxyadenosine, 2'-deoxyadenosine, 2',3'-dideoxyinosine, 2',3'-dideoxycytidine were purchased from Calbiochem-Behring, while 2',3'-dideoxyguanosine and 2',3'-dideoxythymidine were purchased from Pharmacia. 3'-Deoxyadenosine (cordycepin) was purchased from Boehringer-Mannheim. 9-f3-D-Arabinofuranosyladenine and 2',3',5'-trideoxyadenosine were generously provided by D. Johns, J. Driscoll, and G. Milne. Cells. We have described the method for generating normal tetanus toxoid-specific T-cell clones (20) , and one such normal OKT4' clone (TM3) was used in this study. Characteristics of clone TM3 have been described elsewhere (17) . An immortalized OKT4' T-cell clone (ATH8) was obtained by cloning a normal tetanus-toxoid-specific T-cell line in the presence of human T-lymphotropic virus type I (HTLV-I)-producing cells as described (20) . Clone H9 is an OKT4' T-cell line that is permissive to HTLV-III/LAV replication but partially resistant to the HTLV-III/LAV cytopathic effect as described by Popovic et al. (1) .
HTLV-Ill/LAV Cytopathic Effect Assay. HTLV-III/LAV cytopathic effect assays were performed as described (11 Days in culture distinct copies of HTLV-I in its genome when assessed by Southern blot hybridization using a radiolabeled HTLV-I cDNA probe but does not produce detectable amounts of HTLV-I gag proteins (unpublished results).
In our system, HTLV-III/LAV (as cell-free virus) exerts a profound cytopathic effect on the target T cells by day 4 in culture, and by day 10, >98% of cells have been killed by the virus (Fig. la) . The killing of cells can be monitored quantitatively as a function of the starting dose of virus particles (Table 1) . When ATH8 cells were used in a 7-day assay, 5 virus particles per cell represented the minimum cytopathic dose of virus. In the experiments reported below, 2000 or 3000 virus particles per cell were used to test various compounds under conditions of substantial virus excess.
Protection of Helper/Inducer T Cells by 2',3'-Dideoxynucleosides Against HTLV-II/LAV Cytopathic Effect. Fig. 1 (b-e) and Fig. 2 show the potent protective effect of 2',3'-dideoxynucleosides on the survival and growth ofATH8 cells when exposed to HTLV-III/LAV. We found that concentrations of >10 ,uM 2',3'-dideoxyadenosine, 2',3'-dideoxyguanosine, and 2',3'-dideoxyinosine, as well as concentrations of >0.5 AM 2',3'-dideoxycytidine completely protected ATH8 cells and enabled them to survive and grow. These compounds exhibited a strong anti-viral effect at doses that were lower by a factor of 10 to 20 than those that inhibited growth of the target cells when no virus was present. Under our experimental conditions, 2',3'-dideoxythymidine required relatively high concentrations to exert a protective effect, and unlike the other comparable dideoxynucleosides tested, its capacity to nullify the cytopathic effect of the virus was lost on day 10 of the culture (Fig. le and Fig. 2 , Bottom).
The protective effects of 2',3'-dideoxyadenosine, -inosine, and -cytidine were confirmed in normal helper/inducer TM3 cells that were cocultured with irradiated H9/HTLV-IIIB cells (Fig. 3) . When cultured in the absence of the nucleosides, by day 14, H9/HTLV-IIIB cells exerted a substantial cytopathic effect on the TM3 population, resulting in a profound decrease in the number of total viable TM3 cells as compared to the virus-unexposed TM3 populations. However, 2',3'-dideoxyadenosine (100 ,uM), -inosine (100 ,uM), and -cytidine (5 ,uM) clearly blocked the cytopathic effect of HTLV-IIIB.
Inhibition of HTLV-Ill/LAV p24 gag Protein Expression in H9 Cells by 2',3'-Dideoxynucleosides. These anti-viral effects were confirmed in a different system by using the expression of the HTLV-III/LAV p24 gag protein in H9 cells (Fig. 4) Fig. 5 . The congeners differed only in their sugar moieties. In these experiments, the 2',3'-dideoxyadenosine completely protected the target ATH8 cells against lysis by the virus during the course of the culture. The other compounds failed to inhibit the cytopathic effect of the virus. The adenosine arabinoside did not mediate an anti-viral effect even when 2'-deoxycoformycin was added (data not shown).
2',3'-Dideoxynucleosides Do not Inhibit Functions of T Cells at Concentrations that Block Replication and Cytopathic Effect of HTLV-Iu/LAV. We then tested the effects of the various 2',3'-dideoxynucleosides on the antigen-specific and lectininduced reactivity of normal lymphocytes in vitro (Table 2) . We used a normal helper/inducer T-cell clone TM3 to monitor the effects of the compounds on antigen-driven activation, and normal circulating lymphocytes to monitor the effects on phytohemagglutinin-and pokeweed mitogendriven activation. Concentrations of these compounds including those that were 10-to 20-fold higher than those necessary to block the in vitro infectivity and cytopathic effect of HTLV-III/LAV left the in vitro immune reactivity of normal T cells basically intact. DISCUSSION The data reported here indicate that any 2',3'-dideoxynucleoside tested has the potential to function as an anti-viral agent against the replication of HTLV-III/LAV. (In the case of 2',3'-dideoxyinosine, the anti-viral effect could theoretically be mediated by a salvage pathway conversion to either 2',3'-dideoxyadenosine or 2',3'-dideoxyguanosine.) As the 2',3'-dideoxynucleosides are successively phosphorylated to yield 2',3'-dideoxynucleoside-5'-triphosphates, they become analogues of 2'-deoxynucleotides that are the natural substrates for cellular DNA polymerases and viral reverse transcriptases. In this context, the lack of activity against HTLV-III/LAV that we found using 2',3',5'-trideoxyadenosine (Fig. 5e ) is very likely a consequence of the unavailability of the 5' site to undergo phosphorylation.
The mechanisms by which 2',3'-dideoxynucleosides suppress the replication of HTLV-III/LAV are not known. It is known that the 5'-triphosphate product of 2',3'-dideoxyaden- osine, -dideoxyguanosine, -dideoxycytidine, and -dideoxythymidine can rather easily inhibit cellular DNA polymerases ,B and y, as well as viral reverse transcriptase (vide infra), but not mammalian DNA polymerase a (22) (23) (24) (25) (26) . DNA polymerase a is assumed to be the key DNA synthetic enzyme for DNA replication during cell division, and it also has a role in DNA repair (26) (27) (28) converted to metabolites that differ from the expected phosphorylation products (26) , and therefore, one must consider the possibility that the effects reported here are mediated by as yet unidentified metabolites. Moreover, it is possible that the various dideoxynucleosides might not all be metabolized in the identical way in virally infected and uninfected cells.
Regardless of the mechanism(s), the results reported here demonstrate that a simple chemical modification of the sugar moiety can predictably convert a normal substrate for nucleic acid synthesis into a potent compound with the capacity to inhibit the replication and cytopathic effect of HTLV-III/LAV. These results might have implications in the development of new strategies for the pharmacologic intervention against pathogenic human retroviruses in vivo.
